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Background: Provoked vestibulodynia (PVD), a frequent form of chronic genital pain, is associated with decreased
sexual function for afflicted women, as well as impoverished sexual satisfaction for women and their partners. Pain
and sexuality outcomes for couples with PVD are influenced by interpersonal factors, such as pain catastrophizing,
partner responses to pain, ambivalence over emotional expression, attachment style and perceived relationship and
sexual intimacy. Despite recommendations in the literature to include the partner in cognitive-behavioral therapy
targeted at improving pain and sexuality outcomes, no randomized clinical trial has tested the efficacy of this type
of intervention and compared it to a first-line medical intervention.
Methods: This bi-center, randomized clinical trial is designed to examine the efficacy of cognitive-behavioral couple
therapy compared to topical lidocaine. It is conducted across two Canadian university-hospital centers. Eligible
women diagnosed with PVD and their partners are randomized to one of the two interventions. Evaluations are
conducted using structured interviews and validated self-report measures at three time points: Pre-treatment
(T1: prior to randomization), post-treatment (T2), and 6-month follow-up (T3). The primary outcome is the change in
reported pain during intercourse between T1 and T2. Secondary outcomes focus on whether there are significant
differences between the two treatments at T2 and T3 on (a) the multidimensional aspects of women’s pain and
(b) women and partners’ sexuality (sexual function and satisfaction), psychological adjustment (anxiety, depression,
catastrophizing, self-efficacy, and quality of life), relationship factors (partner responses and dyadic adjustment) and
self-reported improvement and treatment satisfaction. In order to detect an effect size as small as 0.32 for secondary
outcomes, a sample of 170 couples is being recruited (27% dropout expected). A clinically significant decrease in
pain is defined as a 30% reduction.
Discussion: The randomized clinical trial design is the most appropriate to examine the efficacy of cognitive-behavioral
couple therapy, a recently developed and pilot-tested psychosocial intervention for couples coping with PVD, in
comparison to a frequent first-line treatment option, topical lidocaine. Findings from this study will provide important
information about empirically supported treatment options for PVD, and inform future treatment development and
research for this patient population.
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Chronic pain problems involving the female reproductive
system represent major health concerns for women. Often
misunderstood and misdiagnosed or ignored, gynecologic
or genital pain conditions carry a heavy personal cost to
patients and a significant financial burden to society, with
women consulting as many as 4 to 6 physicians about the
pain [1]. Vulvodynia, or chronic unexplained vulvar pain,
is an example of female genital pain. Recent population-
based surveys suggest that, by 40 years of age, 7 to 8% of
women report vulvodynia-like symptoms [2]. Provoked
vestibulodynia (PVD) – an acute recurrent pain localized
within the vulvar vestibule and experienced primarily dur-
ing intercourse – is suspected to be the most frequent type
of vulvodynia in premenopausal women [3].
While not one clear etiologic pathway exists for all
women with PVD, continuing research points to a multi-
factorial understanding, with certain factors presenting as
more common among women with PVD compared to
women without this type of pain. These factors include
early menarche (younger than or equal to 11 years of age
[4]), repeated yeast infections [5], polymorphisms in genes
regulating inflammatory response [6], nociceptor prolifera-
tion and sensitization [7,8], lower touch and pain thresh-
olds [9], and pelvic floor muscle dysfunction [10]. The
essential result is that the pain modulation process is less
efficient in women with PVD [11]. Extending beyond the
biological to accommodate a biopsychosocial model of
pain, there is a growing body of research highlighting the
significance of psychosocial factors as robust predictors of
pain and associated disability.
Cross-sectional research with a sample of women with
PVD showed that increased hypervigilance to and fear of
pain, and higher pain catastrophizing were significantly
associated with increased pain experiencing during inter-
course [12]. From this same study, greater anxiety and
avoidance were associated with poorer sexual function,
and lower pain self-efficacy was related to worse pain
and sexual function outcomes. As for interpersonal fac-
tors, partner responses to pain are thought to reinforce
and perpetuate the pain experience of patients [13-16].
The most studied types of partner responses to PVD are
solicitous (demonstrations of sympathy), negative (dem-
onstrations of anger), and facilitative (encouraging adap-
tive coping). In a cross-sectional examination, increased
solicitous and decreased facilitative partner responses
were associated with higher pain intensity, and lower
negative and higher facilitative partner responses were
associated with increased sexual satisfaction for women
[13,17]. Further examination of these relationships indi-
cated that the associations were respectively mediated by
pain catastrophizing and relationship satisfaction [14].
Using a daily-diary design, it was found that women re-
ported improved sexual functioning on days when theyperceived partner responses to pain as more facilitative
[16]. Therefore, cognitions and behaviors relating to
pain, such as pain self-efficacy, catastrophizing and part-
ner responses to pain, represent avenues through which
interventions might target pain and sexuality outcomes.
More affective interpersonal factors have also shown
to be related to pain and sexual outcomes. Among a
sample of couples with PVD, women’s self-reported rela-
tionship and sexual intimacy were significantly associ-
ated with their sexual function, sexual satisfaction and
pain self-efficacy, suggesting the potential protective in-
fluence of a couple’s intimacy for sexual well-being in
the context of pain [18]. Similarly, low ambivalence over
emotional expression in both partners, indicating they
are comfortable with the way they express emotions,
was significantly linked to better psychological, sexual
and relational outcomes [19]. Further examination of
dyadic factors related to PVD has shown that the associ-
ation between a woman’s insecure attachment style and
lower sexual functioning was mediated by lower levels of
sexual assertiveness [20]. Taken together, these studies
highlight the importance of fostering communication,
both expression and assertion, in couples coping with
PVD. Although empirical evidence continues to mount
in support of the important role of relational variables in
the pain and psychosexual sequelae of PVD, many treat-
ment options target the pain primarily and no study to
date has examined the efficacy of a treatment that incor-
porates systematic inclusion of the partner.
Despite the wide variety of treatment options, there is a
dearth of prospective, controlled studies assessing their ef-
ficacy. Localized interventions include topical lidocaine
[21], biofeedback [22], pelvic floor physical therapy [23],
topical use of estradiol and testosterone compound [24]
and vestibulectomy (surgery) [25]. Systemic interventions
include tricyclic antidepressants [26]. Psychotherapeutic
interventions include cognitive behavioral therapy (CBT)
focusing on reducing pain and improving sexuality [27].
Topical lidocaine is currently recommended as an effect-
ive first-line intervention for PVD [28-30]. Two surveys
confirmed that a local anesthetic, and/or local measures
including lidocaine, are the most commonly used inter-
vention (89% and 83.8%, respectively), with 52% of physi-
cians choosing lidocaine as a first-line therapy [31,32].
Lidocaine is thought to act peripherally by reducing
nociceptor sensitization [33]. Zolnoun and colleagues [34]
hypothesized that long-term use of overnight topical
lidocaine may minimize feedback amplification of pain,
and their prospective study found that nightly applications
of 5% lidocaine resulted in a significant pre- to post-
treatment decrease in self-reported pain and an increase
in intercourse frequency. A randomized trial comparing
topical lidocaine and electromyographic biofeedback
showed that both treatments yielded significant decreases
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functioning [22]. Using the tampon-test (that is, change in
pain experience during the insertion and removal of a
tampon, on a scale of 0 to 10), a randomized, double-
blinded, placebo controlled trial examining the differential
efficacy of lidocaine and the tricyclic antidepressant desip-
ramine, showed that none of the active treatment arms
demonstrated significantly greater pain reductions than
the placebo, with all treatment arms resulting in pre- to
post-treatment pain decreases [33]. However, the study
design had limitations including a sample size smaller than
statistically recommended, perhaps obscuring treatment
effect. Further, 21 to 38% of women reported no sexual ac-
tivity during the 12-week trial [33], suggesting that this
sample may not be representative of partnered women
who remain sexually active. Moreover, the tampon-test is
not representative of the pain a woman experiences during
intercourse. Given the multifaceted nature of the etiology
and impact of PVD, a treatment that can target pain and
also psychological, sexual, and relationship consequences
would have a presumed advantage over one targeting only
biomedical aspects of PVD.
In the first randomized clinical trial (RCT) examining
treatment for PVD, vestibulectomy demonstrated the most
significant reductions in pain during intercourse at post-
treatment; however, all interventions, including group-
CBT, showed positive outcomes for sexual function and
psychological adjustment [27]. At 2.5 year follow-up,
women assigned to CBT did not differ from those assigned
to vestibulectomy in terms of pain during intercourse [35].
Another RCT examining the efficacy of individual CBT for
vulvar pain compared to a supportive psychotherapy
demonstrated that CBT yielded significantly greater im-
provements in pain and sexual function from pre- to post-
treatment, with gains maintained at 1 year follow-up [36].
These findings suggest that CBT may yield a positive im-
pact on more dimensions of PVD than does a first-line
medical treatment.
A systematic review of PVD treatment studies con-
cluded that because behavioral treatments yield com-
parable success to several medical interventions but
with no negative side effects, CBT represents an en-
couraging non-invasive option that can target pain as
well as psychosexual consequences experienced by the
woman and her partner [25]. However, while CBT for
PVD has been successfully investigated in group and in-
dividual format, it has never been examined in couple
format. Moreover, CBT formatted for the couple is the
most common and recommended way that CBT for sex-
ual dysfunction is delivered in clinical settings, hence
the form of CBT that is most representative of clinical
reality [37].
The growing body of work focusing on the interper-
sonal aspects of PVD has led to the development of anovel, targeted cognitive-behavioral couple therapy
(CBCT). CBCT was pilot-tested for feasibility and pre-
liminary effectiveness, showing significant pre- to post-
treatment improvements in pain during intercourse and
sexual function for women with PVD, and sexual satis-
faction for both members of the couple [38]. Therefore,
the primary goal of the present RCT is to evaluate the
efficacy of CBCT in comparison to one of the most
commonly prescribed first-line medical interventions,
topical lidocaine, in the reduction of pain during inter-
course at post-treatment. Secondary research goals in-
clude the examination of differences between the two
treatments at post-treatment and 6 month follow-up on:
(a) the multidimensional aspects of women’s pain; (b)
women and partners’ sexuality (sexual function and
satisfaction, frequency of intercourse); (c) psychological
adjustment (anxiety, depression, catastrophizing, self-
efficacy, attributions and quality of life); (d) relationship
factors (partner responses and dyadic adjustment); and (e)
self-reported improvement and treatment satisfaction.
Childhood trauma and co-morbid pain conditions are be-
ing considered as moderators of treatment response.
Methods/design
Design
The present study is a bi-center trial using an intent-
to-treat analysis strategy, designed to compare the effi-
cacy of CBCT and topical lidocaine for the treatment of
PVD. This design is based on previously conducted
RCTs assessing treatments for PVD and recommenda-
tions outlined in the Initiative on Methods, Measurement,
and Pain Assessment in Clinical Trials (IMMPACT)
guidelines for chronic pain clinical trials [39]. This trial is
comprised of three evaluation points (pre-treatment,
post-treatment and 6 month follow-up) carried out via
structured interviews and online validated self-report
questionnaires.
Research sites
This research is supported by an operating grant from the
Canadian Institutes of Health Research, and has ethical ap-
proval from the Research Ethics Committee of the Centre
Hospitalier de l’Université de Montréal (13.156) and the
IWK Health Centre Research Ethics Board (1014930). The
study involves collaborations from researchers from the
following institutions: Centre Hospitalier de l’Université de
Montréal, the Université de Montréal, the IWK Health
Centre, and Dalhousie University.
Participants
Participant eligibility criteria are described in Table 1.
These criteria ensure recruitment of a homogeneous
sample of sexually active women diagnosed with PVD.
As part of the eligibility assessment, a comprehensive
Table 1 Eligibility criteria
Level 1 Level 2 Level 3
Inclusion criteria Inclusion criteria Exclusion criteria
Participants with PVD Participants with PVD Participants with PVD
- Pain during intercourse which a) is
subjectively distressing, b) occurs on 80% of
intercourse attempts, and c) has lasted for at
least 1 year
- Significant pain in one or more locations of the
vestibule during the gynecological examination,
which is operationalized as a minimum patient
pain rating of 4 on a scale of 0 to 10
- Vulvar pain not clearly linked to intercourse or
pressure applied to the vestibule
- Pain limited to intercourse and other
activities involving pressure to the vestibule
- Diagnosis of PVD
- Presence of one of the following: a) active
infection, b) vaginismus (as defined by DSM-IV),
e) dermatologic lesion, f) pregnancy or planning
a pregnancy, g) known allergy to lidocaine, and
h) menopause.
- Sexually active as a couple in the last
3 months (not limited to but must include
some attempted vaginal penetration)
- Receiving treatment for PVD
- Cohabiting and/or been a couple for at least
6 months and have at least 4 in-person
contacts per week
Participants with PVD and Partners
- Aged 18–45 years
- Presence of major medical and/or psychiatric
illness in either partner
Participants with PVD and Partners
- Receiving couple therapy
- Read and write in English and/or French,
with regular access to internet and email
- Presence of severe relational distress and/or
high level of physical conflict
- Age: 18 years or older
DSM-IV Diagnostic and Statistical Manual of Mental Disorders-IV; PVD provoked vestibulodynia.
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dardized protocol. This protocol, successfully used in a
previous RCT [27], is outlined in Table 2. Women with
PVD who present with a concomitant infection are treated
and then asked to come in again to repeat the gynecologic
protocol to determine eligibility.Treatments
Cognitive-behavioral couple therapy
CBCT is delivered over 12 weeks, with couples attending a
75-minute therapy session once per week. CBCT was
adapted from Bergeron and colleagues Cognitive-Behavioral
Pain and Sex Therapy manual [40] – a treatment manual
outlining a CBT group-therapy for women with PVD – to
include recent and pertinent findings about pain-related,
sexuality, interpersonal and psychological factors associated
with PVD. Throughout the study, CBCT therapists take
part in weekly supervision sessions with a psychologist with
training and expertise in CBCT for pain and sexuality.
Adherence to the treatment manual is monitored via DVD
recordings of therapy sessions, which are reviewed on an
ongoing basis by the principal investigators. If any devia-
tions are noted, therapists are given additional supervision.
An outline of select CBCT interventions is provided in
Table 3. No adverse reactions associated with CBT for PVD
have been noted in the literature, yet all participants are
instructed to contact research personnel should they experi-
ence any adverse events as part of treatment.Topical lidocaine
Participants perform nightly applications of a 5% lidocaine
ointment on the vulvar vestibule, at the entry of the vagina
(50 mg/g, Lidocaine ointment 5% USP Lidodan, Odan,
tubes of 35 g) for 12 weeks, as described by Zolnoun and
colleagues [34]. In addition, the ointment is applied to a
cotton square kept on the vestibule via the participant’s
underwear overnight to ensure continued 7- to 8-hour
contact. Appropriate written and oral instructions are pro-
vided to participants (Table 4). A research assistant con-
ducts standardized weekly phone calls in order to monitor
potential adverse events. Participants are instructed to in-
form research personnel if they experience any adverse re-
actions. Potential side effects of lidocaine include: skin
irritation such as redness, itching, swelling, burning sensa-
tion, and prickling sensation.Monitoring during treatment
Partner participation is an integral part of the study, inde-
pendent of treatment arm. For CBCT, overall participant-
treatment adherence is measured by monitoring attendance
to CBCT sessions and by asking participants at each session
to rate the frequency of weekly practice of homework exer-
cises. Participants who attend less than 75% of sessions and
do less than 50% of the homework exercises are considered
non-compliant. These numbers are based on the fact that
therapy sessions are an essential component of treatment
whereas it is not clear up to what point homework
Table 2 Gynecology examination protocol
- Brief interview about past medical history, medication, and obstetrical/gynecological history, including painful intercourse
- A one digit single-handed palpation of the following areas: vagina, uterus and adnexa
- A standard bimanual palpation of the uterus and adnexa
- Physician to record participants’ pain rating at each site on a scale of 0 (no pain) to 10 (worst pain ever)
- Physician to note any other physical findings, and note diagnosis
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homework completion are standard aspects of couple
therapy, addressed actively by the therapist at each session,
namely by providing a rationale for each homework exer-
cise and problem-solving before and after taking part in
the exercise. Missed therapy sessions are rescheduled if
notice is provided and at the convenience of the partici-
pants. In order to empirically document therapist adher-
ence to the treatment manual (treatment reliability), two
trained research assistants are independently viewing and
coding a random sample of videotapes representing a
quarter of all therapy sessions. For the topical lidocaine
condition, the weekly phone calls to participants to mo-
nitor adverse events are also intended to facilitate com-
pliance with the application and minimize the risk of
drop-outs. Participants assigned to this condition also
complete a daily diary to document the lidocaine applica-
tion to determine treatment reliability. Participants who
apply the lidocaine less than 75% of the total evenings
comprising the treatment period are considered non-
compliant.Table 3 Cognitive-behavioral couple therapy treatment
outline
Session In-session interventions Homework exercises
1 Discuss treatment expectations Pain and sex journaling
2 Psychoeducation re: provoked
vestibulodynia
Mindfulness breathing
3 Communication: disclosure and
validation
4 Identifying biopsychosocial factors
influencing pain
Pain-localization
5 Role of anxiety for pain and sex Kegel exercises (if
appropriate)
6 Partner and woman responses to
pain
Sensate focus
7 Redefining the sexual narrative Dilatation exercises (if
applicable)
8 Facilitating sexual desire and arousal
9 Psychoeducation re: pain attributions
10 Cognitive defusion and meditation Cognitive defusion
11 Importance of self-assertion Homework choice
12 Discussion: information learned and
tools for the futureRecruitment and follow-up
Participants are being recruited via four centers, all special-
ized in the assessment and treatment of vulvo-vaginal pain:
1) Centre hospitalier de l’Université de Montréal, pavillon
St-Luc, Clinique Vuva, directed by MHM, 2) Clinique A
rue McGill, a sexual health clinic directed by MS, 3) the
IWK Health Centre in Halifax where ID holds a general
gynecology practice, and 4) the Queen Elizabeth II Health
Sciences Centre in Halifax where ID directs a specialized
gynecology-dermatology vulvar clinic. Additionally, women
diagnosed with PVD during clinic visits with collaborating
physicians are informed of the study and given the choice
to participate after they have been fully informed of other
available treatments. Additionally, announcements are be-
ing placed online and in Montreal and Halifax newspapers
describing the study, and flyers and pamphlets are placed
in other gynecology offices of both cities and posted on
university and college bulletin boards. Women agreeing to
participate are asked to confirm their partners’ participa-
tion and are scheduled for a pre-treatment evaluation, in-
cluding a gynecological examination. Both partners sign
the consent form. Following satisfaction of inclusion and
exclusion criteria, eligible couples are randomized to one
of the two treatment options.
Randomization and blinding
Randomization takes place shortly before treatment initi-
ation (maximum 2-week delay). Participants are screened
across three levels (see Table 1) for eligibility criteria and
data are entered in the electronic eligibility check web
form created using Dacima™ Clinical Suite (Dacima
Software Inc., Montreal, Quebec, Canada). Participants
meeting eligibility criteria are randomized to either CBCT
or lidocaine, such that an approximately equal number of
CBCT and lidocaine participants are obtained (that is, in-
dividual level randomization is used with stratification by
site). The randomization sequence was written to generate
random permuted blocks with block sizes of four, six and
eight to make the sequence difficult to predict without
leading to a major imbalance in numbers between treat-
ment groups if a block is incomplete at the end of recruit-
ment. Participants found ineligible are excluded and
marked as such. To keep interviewers and assessors blind
to the treatment condition, participants are instructed not
to reveal the treatment to which they were assigned at
Table 4 Lidocaine application instructions
At bedtime
Step 1 First wash hands thoroughly then make sure that targeted region is also clean. Dry by dabbing region with a towel (avoid
vigorously rubbing)
Step 2 Apply a small quantity of ointment (the size of a marble) directly on the vulvar vestibule (see the diagram on the next page).
Next, fold the cotton gauze in 4 (to make a smaller square) and apply the same amount of ointment on the gauze (size of a marble)
You may want to use a mirror to help guide you
Step 3 Cotton underwear may help keep the cotton gauze in place overnight while you sleep. You want to try to keep the lidocaine
ointment in contact with the painful part of your vulvar vestibule for about 8 hours. Remove it when you wake up
Step 4 Wash hands immediately to avoid spreading ointment on unwanted areas
Step 5 Repeat these steps everyday for 12 weeks and fill out your Daily Lidocaine Log everyday!
Note: If you have to use the washroom during the night, repeat these steps to ensure that the ointment is present for the rest of the night.
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pamphlet provided at randomization and at the time of
each assessment.
Outcomes and moderators
Measures were selected based on the need to assess the
multiple dimensions of PVD and the potential impact of
treatments on these different dimensions.
Pre-treatment moderators
Trauma, a potential moderator of treatment response, is
assessed using the Childhood Trauma Questionnaire, a
28-item self-report measure focusing on emotional, phys-
ical, and sexual abuse, as well as physical and emotional
neglect in childhood [41]. Scores range from 5 to 25 for
each type of abuse and a total severity scale can also be
computed. Co-morbid pain conditions, another potential
moderator for participants with PVD, are assessed during
the structured interview.
Primary outcome measure
Pain during intercourse is assessed using a visual analog
scale ranging from 0 to 10, where 0 is no pain at all, and
10 is the worst pain ever, as recommended by the
IMMPACT guidelines for chronic pain clinical trials [39].
Participants report on the average pain experienced in the
preceding month. This measure has been shown to detect
significant treatment effects in women with PVD [27] and
demonstrates a significant positive correlation with other
pain intensity measures. Pain during intercourse is the
main symptom of PVD and the one that most interferes
with quality of life, hence the most relevant measure of
functional outcome.
Secondary outcome measures for participants with
provoked vestibulodynia only
Sociodemographic and vulvo-vaginal pain characteristics
are assessed using a structured interview designed spe-
cifically for these purposes and successfully used in pre-
vious research [27]. During this interview, self-reportedmonthly frequency of intercourse and co-morbid pain
conditions are also assessed.
Pain is also assessed using the McGill Pain Questionnaire
(MPQ) [42], which measures the sensory, affective and
evaluative components of pain. The MPQ, a widely used
adjective checklist, assesses both qualitative and quantita-
tive aspects of pain. The Pain Rating Index of the MPQ
scale is also being used.
Secondary outcome measures for participants with
provoked vestibulodynia and their partners
Partners are also asked to report on their own experi-
ences, such as anxiety and depression symptoms. When
measures relate to pain, such as pain catastrophizing
and pain attributions, they are reporting on their own
catastrophizing and attributions about the woman’s pain.
The only exception is self-efficacy, where the partner
rates his or her perception of the woman’s self-efficacy
vis-à-vis her pain symptoms.
Partner responses to pain from the perspectives of the
women with PVD and their partners are measured with
the West Haven-Yale Multidimensional Pain Inventory –
Significant Other Response Scale (MPI) [43], and the
Spouse Response Inventory – Facilitative subscale (SRI)
[44], which have been adapted to our PVD population and
their partners. These include negative responses, solicitous
responses, and distracting responses for the MPI and fa-
cilitative responses for the SRI. Internal consistency ana-
lyses show alphas ranging from 0.75 to 0.82 for each
subscale of partner and patient versions of the MPI and of
0.87 for patient and partner versions of the SRI [14].
Factor analyses have confirmed that the structures of the
adaptations to couples facing PVD are the same as that of
the original questionnaires. The reliability and validity of
both questionnaires have been widely reported [43-45]. A
partner version of these scales has recently been validated
[46] and used successfully in recent studies [13,14]. Each
scale is analyzed separately.
Dyadic adjustment is assessed using the Couple Satisfac-
tion Index, a 32-item measure of relationship satisfaction,
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precision and power for detecting distinctions in levels of
satisfaction [47]. Unlike similar relationship satisfaction
scales, the Couple Satisfaction Index has been tested with
a sample of couples in varying relationship states (for ex-
ample, dating, engaged, married).
Pain catastrophizing is assessed using the Pain Catastro-
phizing Scale [48], which consists of 13 items scored on a
5-point scale with the end points (0) ‘not at all’ and (4) ‘all
the time’. The Pain Catastrophizing Scale is divided into
three subscales: rumination, magnification and helpless-
ness. It is a reliable and valid measure that has demon-
strated a stable factorial structure across clinical and
general populations [49], and the validated partner version
also shows excellent psychometric properties [50].
Pain attributions are measured with the Extended Attri-
butional Style Questionnaire (EASQ) [51], adapted for use
with women who experience genital pain and their part-
ners. The adapted EASQ consists of 12 hypothetical nega-
tive situations that occur within a genital pain context,
and participants are asked to indicate the major cause of
the situation (open-ended), and then rate the cause on the
following dimensions: internal, global, and stable on a 7-
point Likert scale. The EASQ adapted for genital pain
demonstrates good internal consistency (alpha = 0.84 to
0.86) for subscales and total score, as well as a similar fac-
tor structure to the original EASQ [52].
Anxiety is assessed using the Trait Anxiety scale (20-
items) of the Spielberger State-Trait Anxiety Inventory
[53]. The State-Trait Anxiety Inventory is a 40-item, well-
known and widely used measure of state and trait anxiety
that has demonstrated very good psychometric properties
across populations [54].
Depression is measured via the Beck Depression
Inventory-II, comprised of 21 items, with scores for
most items ranging from 0 (low intensity) to 3 (high in-
tensity) [55]. The Beck Depression Inventory-II has
been validated for use in chronic pain populations [56].
Pain self-efficacy is assessed using the Painful Inter-
course Self-Efficacy Scale [12], which was adapted from
the Arthritis Self-Efficacy Scale [57]. The Painful Inter-
course Self-Efficacy Scale consists of 20 items with three
subscales: self-efficacy for controlling pain during inter-
course, for sexual function, and for other symptoms.
Participants indicate their perceived ability to carry out
sexual activity or to achieve outcomes in pain manage-
ment by responding on a scale from 10 (very uncertain)
to 100 (very certain). Higher scores indicate greater self-
efficacy. The reliability and validity of the original ver-
sion have been established [57] and the factor structure
of the adapted version has been shown to be identical to
that of the original [12]. Partners complete an adapted
version with reference to their beliefs about the woman’s
self-efficacy in the same situations.Quality of life is measured using the Quality Metric™
Short Form 12-question Health Survey. This is a short-
ened version of the widely-used Short Form-36 health
survey and assesses physical and mental health and well-
ness [58]. The IMMPACT guidelines for pain clinical tri-
als recommend the assessment of quality of life [39].
Sexual function is assessed using the Derogatis Interview
for Sexual Functioning – Self-Report, a 25-item self-report
measure of sexual function for men and women [59]. It
assesses five dimensions of sexuality: sexual cognition/
fantasy, arousal, sexual behavior/experience, orgasm, and
sexual drive/relationship. Scores can be calculated for each
dimension and for global sexual functioning. The Deroga-
tis Interview for Sexual Functioning – Self-Report demon-
strates good internal consistency and reliability [59,60].
Sexual satisfaction is measured using the Global Measure
of Sexual Satisfaction Scale, which consists of five items
assessing sexual experiences as good versus bad; pleasant
versus unpleasant; positive versus negative; satisfying ver-
sus unsatisfying; and valuable versus worthless. Internal
consistency of this scale is high (alpha = 0.90), as is test-
retest reliability (r = 0.84) [61].
Woman and partner self-reported improvement (scale
of 0 (worse) to 5 (complete cure)) and treatment satis-
faction (scale of 0 (completely dissatisfied) to 10 (com-
pletely satisfied)) are measured post-treatment and at
6 months follow-up to assess the clinical significance of
results.
Data collection and management
Evaluation
Using the aforementioned measures, evaluations are con-
ducted at three time points: (1) pre-treatment; (2) post-
treatment (immediately following the end of treatment);
and (3) 6 month follow-up (6 months following the end of
treatment). Each time point includes a structured inter-
view and standardized questionnaires. The structured
interview covers demographics, gynecologic history, and
includes the measures of self-reported pain during inter-
course, frequency of intercourse and co-morbid pain con-
ditions. Participants are monitored for the use of other
treatments at each evaluation. Self-report questionnaire
data are collected using Qualtrics Research Suite online
software (Qualtrics, Provo, Utah, USA), to allow for
direct entry of participants’ responses to question-
naires. Qualtrics servers are protected by high-end fire-
wall systems, and vulnerability scans are performed
regularly. Qualtrics can be used by entities that are re-
quired to comply with Health Insurance Portability and
Accountability Act privacy rules.
Compliance
In order to ensure maximum rate of participation in
all follow-up evaluations, several strategies are being
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pointments by a research assistant; (2) participants are
asked to provide several points of contact, including
phone number(s), e-mail address and mailing address for
both women and partners; (3) participants are given a
pamphlet highlighting the importance of their continued
participation; (4) participants receive a remuneration of
$30.00 at each evaluation for their travel costs; and (5)
follow-up appointments are scheduled at participant’s con-
venience (for example, on evenings and weekends). These
strategies are intended to increase compliance with each
phase of the protocol.
Statistical considerations
Sample size, power, and statistical analysis methods
Sample size calculations were based on realistic effect sizes
and average pain reductions yielded by pilot work, previ-
ous clinical trials, and observations made during previous
studies focusing on different treatments for PVD [27,38].
From the published pilot data testing CBCT, the data
show effect sizes as small as d = 0.32. Therefore, using an
effect size d = 0.32 (f = 0.16), P < 0.05, two groups, three
times of measurement and a moderate correlation be-
tween repeated measures, a sample size of 124 is necessary
to detect this effect with adequate power (95%) for this tri-
al’s primary and secondary research questions. Based on
previous work, a potential drop-out rate of 27% at the
6 month follow-up has been added to the sample size cal-
culation, resulting in a total sample of 170 participants
(124/0.73). Sample size calculations were conducted
using GPower 3.1.3 (Heinrich Heine University Düsseldorf,
Düsseldorf, Germany) [62].
Statistical analyses
Data storage and analysis is conducted using IBM SPSS
21.0 statistical software (Armonk, New York, USA). The
suitability of variables for analysis is first examined by
inspecting the univariate and multivariate normality of
distributions. An estimator suitable for multivariate ab-
normality is chosen if necessary (robust maximum likeli-
hood or weighted least squared estimators). Descriptive
statistics of outcome variables are then compiled.
Primary analyses
In accordance with the intent-to-treat design, all partici-
pants in their randomized group are included for the pri-
mary and secondary analyses. As some attrition is possible
in this longitudinal design, missing data is handled using
the full-information maximum likelihood to allow the use
of all data available, even incomplete cases. To attain the
main objective, which is to compare the efficacy of CBCT
versus lidocaine on pain during intercourse post-treatment,
a piecewise growth curve modeling approach is used [63].
In such a model, the change measured over time on thetarget variable is modeled within a growth curve where
two stages are defined (as growth is expected to be differ-
ent between pre- and post-treatment, than with the follow-
up) instead of one as in a typical growth curve model. The
dependent variable is then operationalized as the slope and
intercept of those same variables for both stages. The
model allows for testing the difference between the growth
parameters in both treatment arms, and thus permits esti-
mating the difference in change in both treatments with
95% confidence interval.
Secondary analyses
A similar strategy is used to assess the differences between
treatment groups post-treatment and at 6 months follow-
up for women and partners’ sexuality (sexual function and
satisfaction, frequency of intercourse), psychological ad-
justment (anxiety, depression, catastrophizing, self-efficacy,
attributions and quality of life), relationship factors (part-
ner responses and dyadic adjustment) and self-reported
improvement and treatment satisfaction. A more conser-
vative significance level (alpha of 0.01) is used to account
for the increased number of analyses. With the addition of
interaction terms, childhood trauma and co-morbid pain
conditions are also planned to examine moderation of
treatment response. Moreover, it is also planned to use the
data from this trial for theory-testing, conducting explora-
tory analyses examining the extent to which changes in
partner responses, catastrophizing and self-efficacy predict
changes in pain and sexuality outcomes.
Ethical aspects
This research study has been evaluated and approved by
the respective ethics committees at each recruitment
site. Research coordinators for each site are ensuring
that the study is maintained in concordance with ethical
standards of both sites. All potential participants are in-
formed that their decision to participate or not has no
impact on their medical care. Couples who choose not
to participate, or who do not satisfy treatment eligibility
criteria are referred for appropriate treatment if inter-
ested. Informed consent is obtained from all partici-
pants. The financial compensation that is offered to
participants for their time at evaluation time-points was
determined to facilitate attendance, but not to induce
compliance. This trial is registered at clinicaltrials.gov
NCT01935063.
Discussion
This is the first randomized trial evaluating the efficacy
of a treatment option for PVD in which the partner is
included. The study of interpersonal factors in the ex-
perience of PVD has been neglected when in fact it is
the most ‘interpersonal’ of pain conditions. Limitations
of previously published PVD treatment research include
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of RCTs [22,33]. Few randomized studies have evaluated
behavioral and cognitive-behavioral interventions [27,36],
particularly as compared to standard forms of care. The
use of a RCT design will provide a rigorous test of efficacy
and high level of evidence. The two interventions being
evaluated, CBCT and topical lidocaine, were developed
using empirical findings and previously established treat-
ment procedures. Both treatment protocols are standard-
ized to facilitate uniformity in delivery to all participants,
and therefore improve treatment reliability.
There are some limitations to consider with the present
study design. A separation of the psychosocial and biomed-
ical approach to treating PVD contradicts recommen-
dations made in the literature concerning a multimodal
approach to care, yet this separation is necessary to deter-
mine the efficacy of each intervention and is particularly
important in the testing of the newly developed CBCT.
Similarly, while a homogeneous sample of women with
PVD who are sexually active may not be representative of
all women and couples experiencing pain during sexual
intercourse, it is the homogeneity that allows the interven-
tions to target similar symptoms for all participants and the
current sexual activity that allows for the assessment of the
primary endpoint: pain experienced during sexual inter-
course. Finally, this RCT does not utilize a double-blind
procedure, or a control condition. Given the nature of the
interventions being compared (psychosocial and biomed-
ical), it is not possible for participants to be blinded to their
assigned treatment. Comparing the CBCT to a “placebo
therapy” is difficult to conceptualize and would not have
been ethical as a “placebo therapy” would have required a
substantial time investment from participants with poten-
tially very limited benefits. And while wait-list control con-
ditions were considered, it was thought to be unethical to
withhold active treatment from women in pain.
This clinical trial addresses the urgent need for empir-
ically validated treatments for PVD, the most frequent
type of vulvodynia. The results will provide PVD couples
with scientifically based treatment options, which may
allow them to reduce their pain and improve their sexual
functioning, psychological well-being and relationship.
Moreover, findings from this study may be applicable to
populations coping with sexual dysfunction related to
health concerns.
Trial status
Both research sites for this trial are actively recruiting
participants. The trial is ongoing and has a planned dur-
ation of 3 years, with recruitment running from March
2014 to March 2017.
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